Serial assessment of left ventricular function after XXXX .

@entity1 @entity308 @entity64 @entity908 @entity583 @entity1002
Left ventricular (LV) function is an important predictor of morbidity and mortality after @entity583 ( @entity583 ). Changes in LV function have been examined during the early and late phases after @entity583 , but serial measurements of LV function during the subacute period have not been performed. To assess sequential changes in LV function during the subacute period after @entity583 , we used quantitative two-dimensional echocardiography to examine 22 @entity1 over a 1-year period. Twenty-one of the 22 @entity1 had a Q-wave @entity583 . Eleven had an anterior @entity583 and 10 had an inferior @entity583 ; their peak @entity908 phosphokinase (CPK) was 1213 mIU/ml +/- 14. Three weeks after acute @entity583 , @entity1002 ( @entity1002 ) had increased from 45% to 52%. Seven of 19 @entity1 showed an @entity1002 < 43% at baseline. In five of these @entity1 , @entity1002 improved, but in two @entity1 , @entity1002 was still < 43% in week 3. There was a significant enlargement of LV end-diastolic volume (LVEDV) (94 ml to 112 ml, p < 0.05) across the four observations but no change in LV end-systolic volume (LVESV; 54 ml to 56 ml, p = n.s.). When two groups (G1 [ @entity308 ], @entity1002 < or = 43%; G2 [preserved], @entity1002 > 43%) were compared, the group with @entity308 @entity1002 demonstrated a higher probability of improvement in @entity1002 (34% to 47%, p < 0.001) and @entity64 volume (38 ml to 65 ml, p < 0.01).
